<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Trigeminal neuralgia
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Trigeminal neuralgia
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Trigeminal neuralgia
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Charles C Ho, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Sajid A Khan, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Mark A Whealy, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jeremy M Shefner, MD, PhD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jerry W Swanson, MD, MHPE
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Richard P Goddeau, Jr, DO, FAHA
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jun 23, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Trigeminal neuralgia (TN) is characterized by recurrent brief episodes of unilateral electric shock-like pains, abrupt in onset and termination, in the distribution of one or more divisions of the fifth cranial (trigeminal) nerve that typically are triggered by innocuous stimuli [
         <a href="#rid1">
          1
         </a>
         ]. An overview of TN is presented here. Other causes of facial pain are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/3355.html" rel="external">
          "Overview of craniofacial pain"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1938255585">
         <span class="h1">
          ETIOLOGY AND PATHOPHYSIOLOGY
         </span>
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h2">
          Anatomy
         </span>
         <span class="headingEndMark">
          —
         </span>
         The trigeminal nerve  (
         <a class="graphic graphic_figure graphicRef63085" href="/z/d/graphic/63085.html" rel="external">
          figure 1
         </a>
         ) is the sensory supply to the face and the sensory and motor supply to the muscles of mastication. It has three major divisions:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Ophthalmic (V1)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Maxillary (V2)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Mandibular (V3)
        </p>
        <p>
        </p>
        <p>
         The nerve starts at the midlateral surface of the pons, and its sensory ganglion (gasserian ganglion) resides in the Meckel cave in the floor of the middle cranial fossa.
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h2">
          Mechanisms
         </span>
         <span class="headingEndMark">
          —
         </span>
         Compression of the trigeminal nerve root is the main mechanism of TN, but brainstem lesions account for a small proportion of cases [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Compression of the trigeminal nerve root
         </strong>
         – Most cases of TN are caused by compression of the trigeminal nerve root, usually within a few millimeters of entry into the pons (the root entry zone) [
         <a href="#rid3">
          3
         </a>
         ]. Compression by an aberrant loop of an artery or vein is thought to account for 80 to 90 percent of cases [
         <a href="#rid3">
          3-7
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Other causes of TN via nerve compression include vestibular schwannoma (acoustic neuroma), meningioma, epidermoid or other cyst, or, rarely, a saccular aneurysm or arteriovenous malformation [
         <a href="#rid8">
          8-14
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The mechanism by which compression of the nerve leads to symptoms appears to be related to demyelination in a circumscribed area around the compression [
         <a href="#rid15">
          15,16
         </a>
         ]. Precisely how demyelination results in the symptoms of TN is not entirely clear. Demyelinated lesions may set up ectopic impulse generation, possibly causing ephaptic transmission. Ephaptic cross-talk between fibers mediating light touch and those involved in pain generation could account for the precipitation of painful attacks by light tactile stimulation of facial trigger zones [
         <a href="#rid3">
          3
         </a>
         ]. Furthermore, alteration of afferent input may disinhibit pain pathways in the spinal trigeminal nucleus.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Multiple sclerosis and brainstem lesions
         </strong>
         – Demyelination of one or more of the trigeminal nerve pathways may also be caused by multiple sclerosis, tumors located at the cerebellopontine angle, or other structural lesions of the brainstem. In multiple sclerosis, a plaque of demyelination typically occurs in the root entry zone of the trigeminal nerve [
         <a href="#rid17">
          17,18
         </a>
         ]. In some cases, such brainstem lesions may be present years before the onset of TN symptoms, suggesting a role for chronic inflammation or central sensitization to the development of TN [
         <a href="#rid19">
          19
         </a>
         ]. Vascular compression also has been noted in patients with multiple sclerosis and TN [
         <a href="#rid18">
          18,20
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Tumors of the central nervous system that may present with TN include meningioma, squamous cell carcinoma, lymphoma, and schwannoma [
         <a href="#rid21">
          21
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Central sensitization
         </strong>
         – Evidence for a role of central pain mechanisms includes the presence of refractory periods after a triggered episode, trains of painful sensations after a single stimulus, and latency from the time of stimulation to the onset of pain [
         <a href="#rid22">
          22
         </a>
         ]. In addition, electrophysiologic evidence of central sensitization of trigeminal nociceptive processing has been observed in some patients with TN who have concomitant chronic facial pain [
         <a href="#rid23">
          23
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1112707429">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         TN is a rare condition that affects females more than males [
         <a href="#rid21">
          21,24
         </a>
         ]. The overall prevalence of TN is &lt;0.1 percent [
         <a href="#rid25">
          25-27
         </a>
         ]. The annual incidence of TN is 4 to 13 per 100,000 people [
         <a href="#rid25">
          25,28
         </a>
         ]. Despite its low incidence, TN is one of the more frequently seen neuralgias in the older adult population. The incidence increases gradually with age; most idiopathic and classic TN cases begin after age 50, although onset may occur in the second and third decades or, rarely, in children [
         <a href="#rid21">
          21,29
         </a>
         ].
        </p>
        <p>
         The male-to-female prevalence ratio of TN ranges from 1:1.5 to 1:1.7 [
         <a href="#rid24">
          24,30
         </a>
         ]. This female predominance may be related to the increased longevity of females compared with males. Rare familial cases have been reported, but the vast majority of patients have sporadic disease [
         <a href="#rid31">
          31,32
         </a>
         ].
        </p>
        <p>
         Although data are not entirely consistent, hypertension may be a risk factor for the development of TN [
         <a href="#rid30">
          30,33-35
         </a>
         ]. There is also some evidence that migraine is a risk factor for TN [
         <a href="#rid36">
          36
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h1">
          CLINICAL FEATURES
         </span>
         <span class="headingEndMark">
          —
         </span>
         TN is defined clinically by paroxysmal, stereotyped attacks of usually intense, sharp, superficial, or stabbing pain in the distribution of one or more branches of the fifth cranial (trigeminal) nerve  (
         <a class="graphic graphic_figure graphicRef70877" href="/z/d/graphic/70877.html" rel="external">
          figure 2
         </a>
         ).
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Trigeminal distribution
         </strong>
         – The pain of TN is strictly limited to the distribution of the trigeminal nerve. The pain most often involves the V2 and/or V3 subdivisions of the trigeminal nerve [
         <a href="#rid1">
          1
         </a>
         ]. However, isolated involvement of the V1 subdivision occurs in &lt;5 percent of patients with TN [
         <a href="#rid24">
          24
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Paroxysmal pain
         </strong>
         - The pain of TN tends to occur in paroxysms and is maximal at or near onset. Facial muscle spasms can be seen with severe pain. This finding gave rise to the older term for this disorder, tic douloureux. The pain is often described as electric, shock-like, or stabbing. It usually lasts from one to several seconds, but may occur repetitively, anywhere from 0 to more than 50 times a day [
         <a href="#rid2">
          2,27,37
         </a>
         ]. A refractory period of several minutes during which a paroxysm cannot be provoked is common. Some patients with longstanding TN may have continuous dull pain that is present between paroxysms of pain. Unlike some other facial pain syndromes, TN typically does not awaken patients at night.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Unilateral
         </strong>
         – TN is typically unilateral. Occasionally the pain is bilateral over time, though rarely on both sides simultaneously [
         <a href="#rid38">
          38
         </a>
         ]. In a review of 439 patients with TN, symptoms were unilateral in 81 percent [
         <a href="#rid21">
          21
         </a>
         ]. Bilateral involvement may occur in patients with TN caused by multiple sclerosis and connective tissue disorders such as Sjögren's disease, sarcoidosis, and systemic lupus erythematosus [
         <a href="#rid21">
          21,39
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Trigger zones
         </strong>
         – Nearly all patients with TN experience triggered pain [
         <a href="#rid2">
          2,27,37,40,41
         </a>
         ]. Trigger zones in the distribution of the affected nerve are common and are often located near the midline. Lightly touching these zones often triggers an attack, leading patients to protect these areas [
         <a href="#rid42">
          42
         </a>
         ]. Trigger zones can sometimes be demonstrated on physical examination. Other triggers of TN paroxysms include chewing, talking, brushing teeth, cold air, smiling, and/or grimacing [
         <a href="#rid24">
          24,42
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Autonomic symptoms
         </strong>
         – Autonomic symptoms, usually mild or moderate, can occur in association with attacks of TN in the V1 trigeminal distribution, including lacrimation, conjunctival injection, and rhinorrhea [
         <a href="#rid24">
          24,43,44
         </a>
         ]. The presence of autonomic features, particularly when prominent or severe, is suggestive of the syndromes of short-lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing (SUNCT) and short-lasting unilateral neuralgiform headache attacks with autonomic symptoms (SUNA). (See
         <a class="local">
          'Differential diagnosis'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/3336.html" rel="external">
          "Short-lasting unilateral neuralgiform headache attacks: Clinical features and diagnosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Continuous pain
         </strong>
         – Continuous pain between attacks is present in many patients with TN. It is usually milder than the paroxysmal attacks and is typically characterized as dull or tingling, though the intensity and quality may fluctuate [
         <a href="#rid27">
          27
         </a>
         ]. In a cohort of 158 patients with TN from a tertiary headache center, concomitant persistent pain was present in about one-half of patients [
         <a href="#rid24">
          24
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Some reports describe patients with a history of "pretrigeminal neuralgia," a dull, continuous, aching pain in the jaw that evolves over time into TN [
         <a href="#rid45">
          45-47
         </a>
         ]. This brief, milder pain is sometimes suspected to have a dental origin, and unnecessary dental procedures have been performed in some cases [
         <a href="#rid48">
          48
         </a>
         ]. On the other hand, TN can be precipitated by dental procedures (eg, dental extraction), resulting in increased confusion about the precise etiology of this problem [
         <a href="#rid45">
          45
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         The course of TN is variable, as discussed below. (See
         <a class="local">
          'Prognosis'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h1">
          EVALUATION AND DIAGNOSIS
         </span>
        </p>
        <p class="headingAnchor" id="H2568447195">
         <span class="h2">
          Clinical diagnosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         The diagnosis of TN is based upon the characteristic clinical features described above, primarily paroxysms of pain in the distribution of the trigeminal nerve. Once the diagnosis of TN is suspected on clinical grounds, a search for secondary causes should be undertaken.
        </p>
        <p>
         The International Classification of Headache Disorders, Third Edition (ICHD-3) diagnostic criteria for TN are as follows [
         <a href="#rid1">
          1
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A) Recurrent paroxysms of unilateral facial pain in the distribution(s) of one or more divisions of the trigeminal nerve, with no radiation beyond, and fulfilling criteria B and C
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         B) Pain has all of the following characteristics:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Lasting from a fraction of a second to two minutes
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Severe intensity
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Electric shock-like, shooting, stabbing, or sharp in quality
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         C) Precipitated by innocuous stimuli within the affected trigeminal distribution
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         D) Not better accounted for by another ICHD-3 diagnosis
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2299025196">
         <span class="h2">
          Determining the etiology
         </span>
         <span class="headingEndMark">
          —
         </span>
         For all patients with suspected TN or those with recurrent attacks of pain limited to one or more divisions of the trigeminal nerve and no obvious cause, neuroimaging is necessary to help determine the mechanism  (
         <a class="graphic graphic_algorithm graphicRef101663" href="/z/d/graphic/101663.html" rel="external">
          algorithm 1
         </a>
         ) [
         <a href="#rid49">
          49
         </a>
         ]. Trigeminal reflex testing is not used routinely in the diagnostic evaluation of TN, but can be helpful for patients who cannot have magnetic resonance imaging (MRI) and for patients with suspected TN who have a nondiagnostic MRI [
         <a href="#rid27">
          27
         </a>
         ]. (See
         <a class="local">
          'Imaging'
         </a>
         below and
         <a class="local">
          'Trigeminal reflex testing'
         </a>
         below.)
        </p>
        <p>
         The International Classification of Headache Disorders, Third Edition (ICHD-3), defines several subtypes of TN according to the underlying cause [
         <a href="#rid1">
          1
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Classic (or classical) TN
         </strong>
         , which develops without apparent cause other than neurovascular compression, fulfilling the ICHD-3 criteria for TN above and requiring demonstration on MRI or during surgery of neurovascular compression (not simply contact), with morphological changes in the trigeminal nerve root. The rationale is as follows. TN found to be related to compression of the trigeminal nerve by a vascular loop, as demonstrated by surgery, could be regarded as secondary by the ICHD-3, but it is not. Most patients do not have surgery, and it is often uncertain as to whether they have neurovascular contact or compression. For this reason, the ICHD-3 uses the term "classical" instead of "primary" for patients with a typical history of TN who have a presumed or demonstrated vascular source of compression as the cause.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Secondary TN
         </strong>
         , defined as TN caused by an underlying disease. Recognized causes include multiple sclerosis, cerebellopontine angle tumor, and arteriovenous malformation. Secondary TN accounts for approximately 15 percent of cases [
         <a href="#rid6">
          6,27
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Idiopathic TN
         </strong>
         , defined as TN with neither electrophysiological tests nor MRI showing significant abnormalities. Idiopathic TN accounts for approximately 10 percent of cases [
         <a href="#rid7">
          7,50
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Patients with trigeminal sensory loss or bilateral involvement are probably at higher risk of secondary TN [
         <a href="#rid6">
          6
         </a>
         ]. Younger age is also probably associated with a higher risk of secondary TN. However, age is not a clinically useful predictor for distinguishing classic TN from secondary TN because there is considerable age overlap. In addition, absence of any of these clinical features (sensory loss, bilateral involvement, younger age) does not rule out a secondary cause for TN.
        </p>
        <p class="headingAnchor" id="H2517563407">
         <span class="h3">
          Imaging
         </span>
         <span class="headingEndMark">
          —
         </span>
         As noted above, we recommend MRI with and without contrast to rule out neurovascular compression or a structural brain lesion (eg, tumor in the cerebellopontine angle, demyelinating lesions including multiple sclerosis) as the cause of TN  (
         <a class="graphic graphic_algorithm graphicRef101663" href="/z/d/graphic/101663.html" rel="external">
          algorithm 1
         </a>
         ) [
         <a href="#rid6">
          6,21,49,51,52
         </a>
         ]. Head computed tomography (CT) is an alternative when MRI is not an option, but MRI and magnetic resonance angiography (MRA) are much preferred because the higher resolution of MRI enables visualization of the trigeminal nerve and small adjacent lesions.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          MRI techniques
         </strong>
         – High-resolution MRI with thin cuts through the region of the trigeminal ganglion and heavy T2 weighting (eg, three-dimensional [3D] T2-weighted MRI using constructive interference in steady-state [CISS] fusion study with the addition of intravenous contrast), is optimal for visualizing the trigeminal nerve in its cisternal and cavernous segments [
         <a href="#rid27">
          27,53
         </a>
         ]. 3D time-of-flight MRA is optimal for visualizing the arteries [
         <a href="#rid27">
          27,54,55
         </a>
         ]. To optimize the detection of possible neurovascular contact, European guidelines recommend a combination of high-resolution sequences: 3D T2-weighted MRI, 3D T1-gadolinium contrast MRI, and 3D time-of-flight MRA [
         <a href="#rid49">
          49
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Imaging confirmation of neurovascular compression
         </strong>
         – For patients with a clinical diagnosis of TN prior to MRI, mere contact of a vessel with the trigeminal nerve on imaging is insufficient to diagnose neurovascular compression as the cause. Rather, there is a consensus that the diagnosis requires imaging confirmation of morphological changes such as dislocation, distortion, atrophy, or compression of the trigeminal nerve at its origin from the pons [
         <a href="#rid1">
          1,27
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In a 2014 meta-analysis of nine blinded case-control studies, neurovascular contact of the trigeminal nerve on MRI/MRA was more frequent with symptomatic nerves compared with asymptomatic nerves (89 versus 36 percent) [
         <a href="#rid7">
          7
         </a>
         ]. Anatomic change (ie, atrophy, distortion, or flattening) of the trigeminal nerve on MRI at the site of vascular contact was more frequent with symptomatic nerves (53 versus 9 percent, odds ratio 11.8, 95% CI 7.79-17.89). Trigeminal root contact alone had a sensitivity and specificity of 66 and 90 percent, respectively. When trigeminal root contact and nerve atrophy coexisted, sensitivity was lower (52 percent) but specificity was increased to 100 percent.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1306134210">
         <span class="h3">
          Trigeminal reflex testing
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although seldom used in clinical practice, trigeminal reflex testing is probably useful for distinguishing classic TN from secondary TN, while trigeminal evoked potentials are not useful for making this distinction [
         <a href="#rid6">
          6,49
         </a>
         ]. Trigeminal reflex testing for TN involves side-to-side comparisons of the ophthalmic, maxillary, and mandibular divisions of the trigeminal nerve. In a guideline review of 628 patients with TN from 10 studies, trigeminal reflex testing for the diagnosis of secondary TN had a sensitivity and specificity of 94 percent and 87 percent, respectively [
         <a href="#rid6">
          6,56
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h1">
          DIFFERENTIAL DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The differential diagnosis of TN includes the conditions discussed above that cause classic TN and secondary TN, mainly compression of the trigeminal nerve by a vascular loop or a nonvascular space-occupying lesion, and demyelination from multiple sclerosis in the pons or root entry zone of the trigeminal nerve.
        </p>
        <p class="headingAnchor" id="H633611965">
         <span class="h2">
          Other causes of trigeminal distribution pain
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although less likely to be confused with TN, the differential diagnosis also includes various causes of painful trigeminal neuropathy, such as acute herpes zoster, postherpetic neuralgia, and trauma to the trigeminal nerve.
        </p>
        <p>
         Painful trigeminal neuropathy encompasses a separate category of conditions that cause predominantly continuous or near-continuous facial pain in the distribution of the trigeminal nerve [
         <a href="#rid1">
          1
         </a>
         ]. Examples include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Painful trigeminal neuropathy attributed to acute herpes zoster
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Trigeminal postherpetic neuropathy
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Painful post-traumatic trigeminal neuropathy
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Painful trigeminal neuropathy attributed to other disorder
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Idiopathic painful trigeminal neuropathy
        </p>
        <p>
        </p>
        <p>
         Painful trigeminal neuropathy, distinct from TN, is defined as facial pain in the distribution(s) of one or more branches of the trigeminal nerve that is caused by another disorder and is indicative of neural damage [
         <a href="#rid1">
          1
         </a>
         ]. Unlike TN, the pain is predominantly continuous or near continuous, and is described most often as burning or squeezing, or a pins and needles sensation. Brief paroxysms of pain may occur but are not predominant.
        </p>
        <p>
         In most cases, painful trigeminal neuropathy can be distinguished from TN by a thorough history and examination. Of note, isolated involvement of the V1 subdivision occurs in &lt;5 percent of patients with TN [
         <a href="#rid24">
          24
         </a>
         ], while V1 is most commonly affected by postherpetic neuralgia (see
         <a class="medical medical_review" href="/z/d/html/5289.html" rel="external">
          "Postherpetic neuralgia"
         </a>
         ). Neuroimaging, preferably with brain magnetic resonance imaging (MRI), can discern the presence of demyelination or mass lesion as the cause of TN.
        </p>
        <p class="headingAnchor" id="H1680776367">
         <span class="h2">
          Dental causes of pain
         </span>
         <span class="headingEndMark">
          —
         </span>
         TN may sometimes be confused with dental causes of pain. Dental pain is usually continuous, intraoral pain that is dull or throbbing, whereas classic TN is typically intermittent pain and sharp. However, classic TN is often triggered by oral manipulations such as chewing and brushing the teeth, which can suggest a dental cause and lead patients to present for dental care prior to seeking a medical evaluation. Furthermore, some patients have a phase of "pretrigeminal neuralgia" characterized by atypical symptoms (eg, jaw or tooth pain) that might mimic dental pain. (See
         <a class="local">
          'Clinical features'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H893769285">
         <span class="h2">
          Other causes of headache and craniofacial pain
         </span>
         <span class="headingEndMark">
          —
         </span>
         Several uncommon causes of headache and craniofacial pain should also be considered in the differential diagnosis of TN.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Short-lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing (SUNCT) and short-lasting unilateral neuralgiform headache attacks with autonomic symptoms (SUNA) are characterized by sudden brief attacks of severe unilateral head pain in orbital, periorbital, or temporal regions, accompanied by ipsilateral cranial autonomic symptoms. Attacks may be triggered by a number of factors, including skin contact. Given the short, stabbing nature of the attacks, the cutaneous triggering, and the association of cranial autonomic symptoms with pain in the trigeminal V1 distribution, the differentiation between SUNCT, SUNA, and TN can be difficult. Some argue that the degree of cranial autonomic features in SUNCT and SUNA is greater than in TN, while others suggest that SUNCT, SUNA, and TN are related conditions that exist on a continuum [
         <a href="#rid57">
          57
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3336.html" rel="external">
          "Short-lasting unilateral neuralgiform headache attacks: Clinical features and diagnosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cluster-tic syndrome is a combination of cluster headache with coexistent TN. (See
         <a class="medical medical_review" href="/z/d/html/3355.html" rel="external">
          "Overview of craniofacial pain", section on 'Cluster-tic syndrome'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Primary stabbing headache is characterized by transient, sharp jabbing pains that occur at variable locations within trigeminal and cervical dermatomes. Most of the stabs of pain last only a few seconds and occur at irregular intervals from one to many times each day. The extratrigeminal location of some or all attacks can differentiate primary stabbing headache from TN. (See
         <a class="medical medical_review" href="/z/d/html/3327.html" rel="external">
          "Primary stabbing headache"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         First bite syndrome is a paroxysmal facial pain induced by the first bite of a meal with subsequent lessening on further bites [
         <a href="#rid58">
          58
         </a>
         ]. Pain can also be precipitated by smelling food. First bite syndrome can be distinguished from TN due to its association with deep parotid lesions, prior surgery that included neck dissection, and lack of cutaneous triggers.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h1">
          MEDICAL TREATMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         Pharmacologic therapy with
         <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">
          carbamazepine
         </a>
         or
         <a class="drug drug_general" data-topicid="9467" href="/z/d/drug information/9467.html" rel="external">
          oxcarbazepine
         </a>
         is the first-line initial treatment for most patients with classic TN (caused by neurovascular compression) and patients with idiopathic TN. Surgery is reserved for patients who are refractory to medical therapy. Although placebo-controlled trials are lacking for the treatment of secondary TN (ie, TN caused by multiple sclerosis or nonvascular compression), it is reasonable to treat the pain associated with secondary TN using the same medications that are employed in classic TN [
         <a href="#rid49">
          49
         </a>
         ]. In our clinical experience, patients with secondary TN often respond well to these drugs. Treatment should also be directed at the underlying condition.
        </p>
        <p class="headingAnchor" id="H741989867">
         <span class="h2">
          First-line therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with TN who require pain control, we recommend initial therapy with
         <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">
          carbamazepine
         </a>
         or
         <a class="drug drug_general" data-topicid="9467" href="/z/d/drug information/9467.html" rel="external">
          oxcarbazepine
         </a>
         .
        </p>
        <p class="headingAnchor" id="H3599276828">
         <span class="h3">
          Carbamazepine
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">
          Carbamazepine
         </a>
         is the best studied treatment for classic TN and is established as effective [
         <a href="#rid2">
          2,6,38,59
         </a>
         ]. Side effects can be a problem but are generally manageable, particularly if low doses are prescribed initially with gradual titration.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Efficacy
         </strong>
         – Four randomized, controlled trials with a total of 147 patients have established the effectiveness of
         <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">
          carbamazepine
         </a>
         (200 to 1200 mg daily) for TN [
         <a href="#rid60">
          60-63
         </a>
         ]. A systematic review and practice parameter published in 2008 from the American Academy of Neurology (AAN) and European Federation of Neurological Societies (EFNS) noted that the treatment response in these trials was robust, with complete or near complete pain control attained in 58 to 100 percent of patients on carbamazepine, compared with 0 to 40 percent of patients on placebo [
         <a href="#rid6">
          6
         </a>
         ]. For the outcome of important pain relief, the number needed to treat was &lt;2. However, carbamazepine was sometimes poorly tolerated, with numbers needed to harm for minor and severe adverse events of 3 and 24, respectively.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Dosing
         </strong>
         – The usual starting dose of
         <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">
          carbamazepine
         </a>
         is 100 to 200 mg twice daily. The dose can be increased gradually over weeks by increments of 200 mg as tolerated until sufficient pain relief is attained. The typical total maintenance dose is 600 to 800 mg daily, given in two divided doses for tablets and extended-release capsules, or four divided doses for oral suspension. The maximum suggested total dose for TN is 1200 mg daily.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Adverse effects
         </strong>
         – Adverse effects of
         <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">
          carbamazepine
         </a>
         include nausea, vomiting, diarrhea, hyponatremia, rash, pruritus, drowsiness, dizziness, blurred or double vision, lethargy, and headache. Slow titration may minimize these effects. Carbamazepine-induced leukopenia is not uncommon, but it is usually benign. Rare but serious adverse effects of carbamazepine include agranulocytosis, aplastic anemia, Stevens-Johnson syndrome, toxic epidermal necrolysis, hepatic failure, drug reaction with eosinophilia and systemic symptoms (DRESS), dermatitis/rash, serum sickness, pancreatitis, lupus syndrome, and hypogammaglobulinemia. (See
         <a class="medical medical_review" href="/z/d/html/2221.html" rel="external">
          "Antiseizure medications: Mechanism of action, pharmacology, and adverse effects", section on 'Carbamazepine'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         We suggest testing for the
         <em>
          HLA-B*15:02
         </em>
         allele in genetically at-risk populations (ie, those with East or South Asian ancestry) before initiating treatment with
         <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">
          carbamazepine
         </a>
         . The
         <em>
          HLA-B*15:02
         </em>
         allele is a genetic susceptibility marker that is associated with an increased risk of developing Stevens-Johnson syndrome and/or toxic epidermal necrolysis. If genetic testing results are positive for the presence of at least one copy of the
         <em>
          HLA-B*15:02
         </em>
         allele, carbamazepine should be avoided.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2010166084">
         <span class="h3">
          Oxcarbazepine
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9467" href="/z/d/drug information/9467.html" rel="external">
          Oxcarbazepine
         </a>
         is an effective drug for TN and one that some experts prefer over
         <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">
          carbamazepine
         </a>
         , citing better tolerability and decreased risk of drug interactions [
         <a href="#rid27">
          27,64,65
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Efficacy
         </strong>
         – The 2008 AAN/EFNS practice parameter identified several randomized controlled trials that compared
         <a class="drug drug_general" data-topicid="9467" href="/z/d/drug information/9467.html" rel="external">
          oxcarbazepine
         </a>
         (600 to 1800 mg daily) with
         <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">
          carbamazepine
         </a>
         in 178 patients with TN [
         <a href="#rid6">
          6
         </a>
         ]. In the pooled analysis, both medications were equally effective, with a &gt;50 percent reduction of attacks achieved by 88 percent or more of patients in both treatment groups.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Dosing
         </strong>
         –
         <a class="drug drug_general" data-topicid="9467" href="/z/d/drug information/9467.html" rel="external">
          Oxcarbazepine
         </a>
         can be started at a total dose of 600 mg daily, given in two divided doses. The dose can be increased as tolerated in 300 mg increments every third day to a total dose of 1200 to 1800 mg daily. As with
         <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">
          carbamazepine
         </a>
         , we suggest testing for the
         <em>
          HLA-B*15:02
         </em>
         allele in genetically at-risk populations (ie, those with East Asian or South Asian ancestry) before initiating treatment with oxcarbazepine. Oxcarbazepine and carbamazepine should be avoided in patients carrying the
         <em>
          HLA-B*15:02
         </em>
         allele unless the estimated benefits clearly outweigh the risks.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Adverse effects
         </strong>
         – Adverse effects of
         <a class="drug drug_general" data-topicid="9467" href="/z/d/drug information/9467.html" rel="external">
          oxcarbazepine
         </a>
         are similar to
         <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">
          carbamazepine
         </a>
         and include nausea, vomiting, diarrhea, hyponatremia, rash, pruritus, drowsiness, dizziness, blurred or double vision, lethargy, and headache. Rare but serious hypersensitivity reactions, including Stevens-Johnson syndrome, toxic epidermal necrolysis, and multiorgan hypersensitivity, have been associated with oxcarbazepine use, usually within the first few weeks of starting the drug. (See
         <a class="medical medical_review" href="/z/d/html/2221.html" rel="external">
          "Antiseizure medications: Mechanism of action, pharmacology, and adverse effects", section on 'Oxcarbazepine'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1588658827">
         <span class="h2">
          Alternatives and adjuncts to first-line therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with TN who are intolerant of or have contraindications to
         <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">
          carbamazepine
         </a>
         and
         <a class="drug drug_general" data-topicid="9467" href="/z/d/drug information/9467.html" rel="external">
          oxcarbazepine
         </a>
         , we suggest treatment with
         <a class="drug drug_general" data-topicid="9545" href="/z/d/drug information/9545.html" rel="external">
          lamotrigine
         </a>
         ,
         <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">
          gabapentin
         </a>
         , or
         <a class="drug drug_general" data-topicid="9062" href="/z/d/drug information/9062.html" rel="external">
          baclofen
         </a>
         . Some patients who are nonresponders to first-line carbamazepine monotherapy may benefit from combination therapy with gabapentin, lamotrigine,
         <a class="drug drug_general" data-topicid="10006" href="/z/d/drug information/10006.html" rel="external">
          topiramate
         </a>
         , baclofen, or
         <a class="drug drug_general" data-topicid="9999" href="/z/d/drug information/9999.html" rel="external">
          tizanidine
         </a>
         . Nevertheless, there are no randomized controlled trials comparing monotherapy with combination therapy for TN.
        </p>
        <p>
         Other experts advise early surgical referral for all patients who fail to respond to first-line therapy with
         <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">
          carbamazepine
         </a>
         or
         <a class="drug drug_general" data-topicid="9467" href="/z/d/drug information/9467.html" rel="external">
          oxcarbazepine
         </a>
         , arguing that they are unlikely to respond to alternative medications for TN [
         <a href="#rid27">
          27,66
         </a>
         ]. (See
         <a class="local">
          'Surgery for medically refractory TN'
         </a>
         below.)
        </p>
        <p>
         There is only limited evidence to support treatment alternatives for patients with TN who are unable to tolerate or do not respond to first-line medical therapy. The 2008 AAN/EFNS practice parameter concluded that
         <a class="drug drug_general" data-topicid="9062" href="/z/d/drug information/9062.html" rel="external">
          baclofen
         </a>
         ,
         <a class="drug drug_general" data-topicid="9545" href="/z/d/drug information/9545.html" rel="external">
          lamotrigine
         </a>
         , and
         <a class="drug drug_general" data-topicid="9773" href="/z/d/drug information/9773.html" rel="external">
          pimozide
         </a>
         are possibly effective for TN [
         <a href="#rid6">
          6
         </a>
         ]. There are weak data to support botulinum toxin injections. A subsequent (2019) systematic review from the European Academy of Neurology concluded that lamotrigine,
         <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">
          gabapentin
         </a>
         , botulinum toxin type A,
         <a class="drug drug_general" data-topicid="9473" href="/z/d/drug information/9473.html" rel="external">
          pregabalin
         </a>
         , baclofen, and
         <a class="drug drug_general" data-topicid="9769" href="/z/d/drug information/9769.html" rel="external">
          phenytoin
         </a>
         can be used as monotherapy or as adjuncts with first-line therapy (
         <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">
          carbamazepine
         </a>
         or
         <a class="drug drug_general" data-topicid="9467" href="/z/d/drug information/9467.html" rel="external">
          oxcarbazepine
         </a>
         ) when first-line agents are ineffective or poorly tolerated [
         <a href="#rid49">
          49
         </a>
         ]. However, the quality of supporting evidence was low to very low.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">
          Gabapentin
         </a>
         – Gabapentin was shown to be possibly effective and to have fewer side effects when compared with
         <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">
          carbamazepine
         </a>
         in a 2016 meta-analysis of 16 randomized controlled trials (all published in Chinese). However, all studies were rated as having poor methodologic quality [
         <a href="#rid67">
          67
         </a>
         ]. Nevertheless, gabapentin is an attractive choice due to its better tolerability compared with first-line agents, relative lack of drug interactions, and a low risk of hepatic or renal toxicity [
         <a href="#rid49">
          49
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9545" href="/z/d/drug information/9545.html" rel="external">
          Lamotrigine
         </a>
         – In a double-blind, placebo-controlled crossover study of 14 patients with TN that was refractory to
         <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">
          carbamazepine
         </a>
         or
         <a class="drug drug_general" data-topicid="9769" href="/z/d/drug information/9769.html" rel="external">
          phenytoin
         </a>
         , adjunct therapy with lamotrigine (400 mg daily) was beneficial for improvement on a composite outcome index [
         <a href="#rid68">
          68
         </a>
         ]. Patients continued taking either carbamazepine or phenytoin for the duration of the trial. Similarly, an open-label study found that lamotrigine was beneficial in 11 of 15 patients with TN once the 400 mg dose was reached [
         <a href="#rid69">
          69
         </a>
         ]. However, the clinical utility of lamotrigine for severe pain is limited by the need to titrate the dose over many weeks, given the risk of rash and other serious adverse effects [
         <a href="#rid70">
          70
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In patients who are not taking other antiseizure medications,
         <a class="drug drug_general" data-topicid="9545" href="/z/d/drug information/9545.html" rel="external">
          lamotrigine
         </a>
         is typically started at 25 mg daily for the first two weeks, and then increased to 50 mg daily for weeks 3 and 4. The dose is then titrated to effect, increasing the total daily dose by 50 mg every one to two weeks up to a maximum of 400 mg. Lamotrigine is dosed once daily as an extended-release formulation and twice daily (in divided doses) as an immediate-release formulation.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         For patients taking an antiseizure medication that induces hepatic enzymes (eg,
         <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">
          carbamazepine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9769" href="/z/d/drug information/9769.html" rel="external">
          phenytoin
         </a>
         , or
         <a class="drug drug_general" data-topicid="9811" href="/z/d/drug information/9811.html" rel="external">
          primidone
         </a>
         ), the initial daily dose of
         <a class="drug drug_general" data-topicid="9545" href="/z/d/drug information/9545.html" rel="external">
          lamotrigine
         </a>
         is 50 mg, titrating upward as needed to 100 mg at week 3, 200 mg at week 5, 300 mg at week 6, and 400 mg at week 7. For patients taking
         <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">
          valproate
         </a>
         , which inhibits hepatic enzymes, the initial daily dose of lamotrigine is 12.5 to 25 mg every other day. The titration transitions to daily dosing at subsequent intervals, with increases of 25 mg every two weeks as needed to a maximum of 200 mg daily. (See
         <a class="medical medical_review" href="/z/d/html/2221.html" rel="external">
          "Antiseizure medications: Mechanism of action, pharmacology, and adverse effects", section on 'Lamotrigine'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9062" href="/z/d/drug information/9062.html" rel="external">
          Baclofen
         </a>
         – Limited evidence from a small double-blind crossover trial suggests that baclofen is beneficial for TN [
         <a href="#rid71">
          71
         </a>
         ]. Treatment with baclofen 40 to 80 mg daily resulted in a reduction in paroxysms in 7 of 10 patients with typical TN, compared with 1 of 10 who received placebo. The starting dose of baclofen is 15 mg daily given in three divided doses, with gradual titration to a maintenance dose of 50 to 60 mg per day. Sedation, dizziness, and dyspepsia can occur with treatment, and the drug should be discontinued slowly since seizures and hallucinations have been reported upon withdrawal. The utility of baclofen is limited by these adverse effects, which typically prevent a sufficient oral dose needed to achieve beneficial pain reduction [
         <a href="#rid27">
          27
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Botulinum toxin injections
         </strong>
         — Botulinum toxin injections may be beneficial for patients with TN, although data are limited. A 2016 systematic review and meta-analysis identified four small placebo-controlled randomized controlled trials with a total of 178 patients that evaluated the use of botulinum toxin A for TN [
         <a href="#rid72">
          72
         </a>
         ]. The overall effect favored botulinum toxin A for the proportion of responders, defined as patients with &gt;50 percent reduction in mean pain score from baseline to endpoint (77 percent, versus 26 percent for placebo, risk ratio 2.87, 95% CI 1.76-4.69). The paroxysm frequency per day was also reduced for patients assigned to botulinum toxin A. Small patient numbers limit the confidence in these results, and further study is required.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Other medications
         </strong>
         – Several other drugs have shown some evidence of efficacy for TN in small, generally lower-quality controlled trials:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="9773" href="/z/d/drug information/9773.html" rel="external">
          Pimozide
         </a>
         , a dopamine receptor antagonist, was more effective than
         <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">
          carbamazepine
         </a>
         in a randomized, double-blind crossover trial of 48 patients with refractory TN [
         <a href="#rid73">
          73,74
         </a>
         ]. There were no dropouts among patients taking pimozide. However, pimozide is seldom used for TN because it has many potentially serious side effects, including sedation, arrhythmias, anticholinergic effects, acute extrapyramidal symptoms, and parkinsonism.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Topical
         <a class="drug drug_general" data-topicid="9558" href="/z/d/drug information/9558.html" rel="external">
          lidocaine
         </a>
         given by intraoral application was more effective than placebo for pain reduction in a two-week, randomized crossover trial of 24 subjects with TN whose pain was most severe in the mouth [
         <a href="#rid75">
          75
         </a>
         ]. However, blinding may have been compromised because of the bitter taste or numbness perceived by some patients when treated with lidocaine.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="9999" href="/z/d/drug information/9999.html" rel="external">
          Tizanidine
         </a>
         appeared to be more effective than placebo in a small one-week trial, but patients who continued the drug in follow-up developed recurrent attacks of TN within one to three months [
         <a href="#rid76">
          76
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Tocainide was as effective as
         <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">
          carbamazepine
         </a>
         at two weeks in a crossover trial of 12 patients with TN [
         <a href="#rid77">
          77
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H372586115">
         <span class="h2">
          Rescue therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Limited low-quality data suggest that intranasal or intravenous infusion of
         <a class="drug drug_general" data-topicid="9558" href="/z/d/drug information/9558.html" rel="external">
          lidocaine
         </a>
         , intravenous
         <a class="drug drug_general" data-topicid="9769" href="/z/d/drug information/9769.html" rel="external">
          phenytoin
         </a>
         or
         <a class="drug drug_general" data-topicid="8480" href="/z/d/drug information/8480.html" rel="external">
          fosphenytoin
         </a>
         , or subcutaneous injections of
         <a class="drug drug_general" data-topicid="9968" href="/z/d/drug information/9968.html" rel="external">
          sumatriptan
         </a>
         can provide analgesia for patients with TN while oral medications are titrated or during breakthrough attacks [
         <a href="#rid78">
          78
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Lidocaine
         </strong>
         –
         <a class="drug drug_general" data-topicid="9558" href="/z/d/drug information/9558.html" rel="external">
          Lidocaine
         </a>
         may be given for acute exacerbations of TN by intranasal aerosol or intravenous administration.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="9558" href="/z/d/drug information/9558.html" rel="external">
          Lidocaine
         </a>
         administered intranasally or intraorally as a 2.4 percent aerosol (32 mg per dose) was reported effective in a retrospective study of 152 patients in China with severe pain from TN [
         <a href="#rid79">
          79
         </a>
         ]. Pain resolution or a greater than 50 percent improvement was reported at 15 and 30 minutes in 78 and 70 percent, respectively. Adverse effects were mild including numbness, bitter taste, and burning in the affected area; no cardiovascular or other systemic adverse effects were reported. Repeat administration for pain recurrence was common and response rate was lower among patients taking high doses of
         <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">
          carbamazepine
         </a>
         or
         <a class="drug drug_general" data-topicid="9467" href="/z/d/drug information/9467.html" rel="external">
          oxcarbazepine
         </a>
         and those with TN symptoms affecting the ophthalmic (V1) division of the trigeminal nerve. Similar short-term benefit was reported in a small placebo-controlled trial of 25 patients with TN using intranasal lidocaine 8 percent (16 mg) [
         <a href="#rid80">
          80
         </a>
         ]. Lidocaine nasal sprays are not commercially available in the United States but may be prepared by a compounding pharmacy.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="9558" href="/z/d/drug information/9558.html" rel="external">
          Lidocaine
         </a>
         administered by intravenous infusion at 5 mg/kg over one hour showed some benefit for up to 24 hours after infusion in a placebo-controlled crossover trial of 20 patients [
         <a href="#rid81">
          81
         </a>
         ]. Intravenous lidocaine administration requires continuous cardiac monitoring with electrocardiogram (ECG) and frequent blood pressure checks.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Phenytoin
         </strong>
         –
         <a class="drug drug_general" data-topicid="9769" href="/z/d/drug information/9769.html" rel="external">
          Phenytoin
         </a>
         or
         <a class="drug drug_general" data-topicid="8480" href="/z/d/drug information/8480.html" rel="external">
          fosphenytoin
         </a>
         treatment has been associated with improvement in TN in case reports and small case series [
         <a href="#rid82">
          82-86
         </a>
         ]. The phenytoin dose is 250 to 1000 mg given intravenously at no more than 50 mg/minute (150 mg phenytoin equivalents [PE]/minute for fosphenytoin) [
         <a href="#rid82">
          82
         </a>
         ]. Alternative weight-based dosing is 15 mg/kg given over 30 to 120 minutes [
         <a href="#rid82">
          82,87
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Sumatriptan
         </strong>
         <strong>
         </strong>
         – The benefit of
         <a class="drug drug_general" data-topicid="9968" href="/z/d/drug information/9968.html" rel="external">
          sumatriptan
         </a>
         at 3 mg given by subcutaneous injection was shown in a small placebo-controlled crossover trial, with improvement persisting for a mean duration of approximately eight hours [
         <a href="#rid88">
          88
         </a>
         ]. Subcutaneous sumatriptan followed by oral sumatriptan 50 mg daily for one week may provide a longer duration of analgesia [
         <a href="#rid89">
          89
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Lacosamide
         </strong>
         – In a retrospective observational study of patients with TN presenting to an emergency department, resolution of acute symptoms following an intravenous infusion of
         <a class="drug drug_general" data-topicid="10268" href="/z/d/drug information/10268.html" rel="external">
          lacosamide
         </a>
         was reported in 49 of 63 patients (78 percent) [
         <a href="#rid86">
          86
         </a>
         ]. Infusion dose ranged from 50 to 400 mg; adverse effects were mild.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3312109688">
         <span class="h2">
          Duration of successful medical therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Periodic attempts to gradually withdraw these drugs are warranted in patients achieving relief of pain with oral medications. The key criterion for attempting a gradual wean is a sustained pain-free interval of at least six to eight weeks on medication; some authors would wait for at least six months before attempting a wean. The taper schedule varies according to the medication and dose but should be slow. The patient should be aware that the likelihood of future pain recurrence is high and would require restarting the medication.
        </p>
        <p class="headingAnchor" id="H20">
         <span class="h1">
          SURGERY FOR MEDICALLY REFRACTORY TN
         </span>
        </p>
        <p class="headingAnchor" id="H701830524">
         <span class="h2">
          Choice of procedure
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with TN refractory to medical therapy, it is reasonable to discuss options for surgical therapy using microvascular decompression, various types of rhizotomy, or gamma knife radiosurgery [
         <a href="#rid2">
          2
         </a>
         ]. The decision to have surgery and the choice among surgical options will be influenced by individual circumstances including patient preference, adverse effect profile of the available techniques, and expertise of the local center.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Patients with classic TN
         </strong>
         - For patients with neurovascular compression confirmed by imaging (see
         <a class="local">
          'Imaging'
         </a>
         above) who are able to tolerate major surgery, we suggest microvascular decompression rather than another surgical procedure. For patients who are poor surgical candidates or prefer to avoid craniotomy, percutaneous ganglion lesion or gamma knife stereotactic radiosurgery are alternatives [
         <a href="#rid90">
          90,91
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Patients with multiple sclerosis and secondary TN
         </strong>
         – Observational data, mainly single-center case series, suggest that some patients with multiple sclerosis (MS) and TN experience at least short-term improvement with interventions including microvascular decompression [
         <a href="#rid92">
          92-94
         </a>
         ], gamma knife radiosurgery [
         <a href="#rid95">
          95
         </a>
         ], and percutaneous ganglion lesioning [
         <a href="#rid96">
          96,97
         </a>
         ]. There is evidence that demyelinating plaque and neurovascular compression coexist in some patients with multiple sclerosis-related TN. (See
         <a class="local">
          'Mechanisms'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Patients with cerebellopontine angle tumor and secondary TN
         </strong>
         – Tumor involving the cerebellopontine angle may cause TN. Most such tumors are benign; the most common ones are meningiomas, vestibular schwannomas, epidermoid cysts, and cholesteatomas. Management of these tumors is reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/5230.html" rel="external">
          "Management of known or presumed benign (WHO grade 1) meningioma", section on 'Large or symptomatic tumors'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5222.html" rel="external">
          "Vestibular schwannoma (acoustic neuroma)", section on 'Management'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5202.html" rel="external">
          "Uncommon brain tumors", section on 'Epidermoid cyst'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6844.html" rel="external">
          "Etiology of hearing loss in adults", section on 'Cholesteatoma'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6306.html" rel="external">
          "Cholesteatoma in children", section on 'Surgical treatment'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Patients with idiopathic TN
         </strong>
         – Surgery may benefit some patients with idiopathic TN (ie, no abnormalities on magnetic resonance imaging [MRI]) but data are limited. Microvascular decompression surgery may identify vascular compression that was not evident on MRI, and if no compressive vessel is found, the surgeon can perform a partial rhizotomy sparing V1. Other strategies include radiosurgery with gamma knife or rhizotomy with radiofrequency, balloon, or glycerol.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H445971700">
         <span class="h2">
          Surgical techniques
         </span>
         <span class="headingEndMark">
          —
         </span>
         Microvascular decompression is invasive, although the overall mortality and complication rates are low. Ablative procedures are less invasive, but recurrence may be more common. However, few surgical treatments for TN have been studied in controlled trials, and most of the evidence comes from observational studies [
         <a href="#rid98">
          98
         </a>
         ]. Definitive conclusions regarding the relative effectiveness of surgical techniques for TN are precluded by the lack of studies directly comparing them [
         <a href="#rid6">
          6
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Microvascular decompression
         </strong>
         – Microvascular decompression is a major neurosurgical procedure that involves craniotomy and the removal or separation of various vascular structures, often an ectatic superior cerebellar artery, away from the trigeminal nerve [
         <a href="#rid99">
          99
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Microvascular decompression appears to be the most effective surgical technique for classic TN (ie, due to neurovascular compression), although comparative randomized trials are lacking [
         <a href="#rid27">
          27,49
         </a>
         ]. The 2008 Academy of Neurology (AAN) and European Federation of Neurological Societies (EFNS) practice parameter identified five studies of microvascular decompression for TN [
         <a href="#rid100">
          100-104
         </a>
         ] that used independent outcome assessment [
         <a href="#rid6">
          6
         </a>
         ]. The practice parameter concluded that initial pain relief was attained in 90 percent of patients, but that pain-free rates declined by one, three, and five years to 80, 75, and 73 percent, respectively. Indirect comparisons of the findings from different surgical studies suggested that microvascular decompression has a longer duration of pain control than other surgical interventions for TN. The average mortality was approximately 0.2 percent; major perioperative adverse events, such as cerebrospinal fluid leaks, infarction, or hematoma, occurred in up to 4 percent of patients, while aseptic meningitis complicated 11 percent [
         <a href="#rid6">
          6
         </a>
         ]. Long-term hearing loss occurred in up to 10 percent of patients, and sensory loss occurred in 7 percent.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Rhizotomy
         </strong>
         – Rhizotomy encompasses a number of percutaneous surgical techniques that are performed by passing a cannula through the foramen ovale under fluoroscopic or computed tomographic (CT) guidance, followed by lesioning of the trigeminal ganglion or root using one of several options [
         <a href="#rid105">
          105,106
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Radiofrequency thermocoagulation rhizotomy, which creates a lesion by application of heat
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Mechanical balloon compression, which uses a Fogarty catheter to compress the gasserian ganglion
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Chemical (glycerol) rhizolysis, which involves the injection of 0.1 to 0.4 mL of glycerol into the trigeminal cistern
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         A small trial of 30 patients with TN found percutaneous radiofrequency ablation reduced pain at one month [
         <a href="#rid107">
          107
         </a>
         ]. The 2008 AAN/EFNS practice parameter identified four uncontrolled case series that used independent outcome assessment of these procedures [
         <a href="#rid6">
          6
         </a>
         ], including two reports of radiofrequency thermocoagulation [
         <a href="#rid108">
          108,109
         </a>
         ], one report of glycerol rhizolysis [
         <a href="#rid110">
          110
         </a>
         ], and one of balloon compression [
         <a href="#rid111">
          111
         </a>
         ]. The AAN/EFNS found that initial pain relief was achieved in 90 percent of patients, but that pain-free rates declined by one year to 68 to 85 percent, by three years to 54 to 64 percent, and by five years to approximately 50 percent [
         <a href="#rid6">
          6
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The major perioperative complication after rhizotomy procedures is meningitis, mainly aseptic, seen in 0.2 percent [
         <a href="#rid6">
          6
         </a>
         ]. There is also a risk of maxillary artery injury and dural laceration overlaying Meckel cave, which could lead to oculomotor nerve injury via thermocoagulation, or inadvertent injection of glycerol into the middle cranial fossa [
         <a href="#rid27">
          27
         </a>
         ]. Mortality is rare. Postoperative dysesthesia, described as a burning, heavy, or aching feeling, occurs in 12 percent [
         <a href="#rid6">
          6
         </a>
         ]. Longer-term sequelae include trigeminal distribution sensory loss in nearly one-half of patients, anesthesia dolorosa in approximately 4 percent, and corneal numbness with risk of keratitis in 4 percent. The incidence of facial numbness is higher with rhizotomy procedures than with microvascular decompression or gamma knife radiosurgery.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Radiosurgery
         </strong>
         – Gamma knife radiosurgery produces lesions with focused gamma radiation [
         <a href="#rid112">
          112
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7063.html" rel="external">
          "Stereotactic cranial radiosurgery", section on 'Gamma Knife'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The therapy is aimed at the proximal trigeminal root since targeting the gasserian ganglion produced poor results [
         <a href="#rid66">
          66
         </a>
         ]. The aiming of the beams is carried out with a stereotactic frame and MRI. The doses used are 70 to 90 grays (Gy). The beams cause axonal degeneration and necrosis [
         <a href="#rid66">
          66
         </a>
         ]. Pain relief with gamma knife surgery occurs after a lag time of approximately one month [
         <a href="#rid66">
          66,113
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The 2008 AAN/EFNS practice parameter [
         <a href="#rid6">
          6
         </a>
         ] identified one randomized controlled trial of gamma knife surgery for TN that compared two different treatment regimens [
         <a href="#rid114">
          114
         </a>
         ] and found no important differences. In addition, the AAN/EFNS [
         <a href="#rid6">
          6
         </a>
         ] identified three case series with independent outcome assessment [
         <a href="#rid115">
          115-117
         </a>
         ]. Complete pain relief at one year was found in up to 69 percent of patients, and at three years in 52 percent [
         <a href="#rid6">
          6
         </a>
         ]. An earlier systematic review found that approximately 75 percent of patients reported complete relief within three months, but the proportion decreased to 50 percent by three years [
         <a href="#rid118">
          118
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         New or worsened facial sensory impairment occurred in 9 to 37 percent, with more bothersome sensory loss or paresthesia found in 6 to 13 percent of patients [
         <a href="#rid6">
          6
         </a>
         ]. However, anesthesia dolorosa is rarely, if ever, a complication of gamma knife surgery.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Linear accelerator radiosurgery has been evaluated for the treatment of TN in retrospective case series [
         <a href="#rid119">
          119,120
         </a>
         ], but no prospective studies or controlled trials are available. (See
         <a class="medical medical_review" href="/z/d/html/7063.html" rel="external">
          "Stereotactic cranial radiosurgery", section on 'Linac'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Peripheral neurectomy
         </strong>
         – Peripheral neurectomy can be performed on the branches of the trigeminal nerve, which are the supraorbital, infraorbital, alveolar, and lingual nerves. Neurectomy is accomplished by incision, alcohol injection, radiofrequency lesioning, or cryotherapy. Cryotherapy involves freezing of the nerve using special probes, in theory to selectively destroy the pain fibers. However, the AAN/EFNS practice parameter and subsequent reviews have noted that the evidence regarding peripheral techniques for the treatment of TN is either negative or inconclusive [
         <a href="#rid6">
          6,27
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Although surgical therapy for TN is generally well tolerated, a feared complication is painful post-traumatic trigeminal neuropathy (anesthesia dolorosa), a condition characterized by persistent, painful anesthesia or hypesthesia in the denervated region [
         <a href="#rid1">
          1
         </a>
         ]. It can be more intolerable than the pain from classic TN itself [
         <a href="#rid121">
          121
         </a>
         ]. Anesthesia dolorosa most frequently occurs as a complication of rhizotomy or thermocoagulation for TN but may also be an uncommon complication of gamma knife surgery. This risk warrants careful decision-making when considering surgical treatment for TN. (See
         <a class="medical medical_review" href="/z/d/html/3355.html" rel="external">
          "Overview of craniofacial pain", section on 'Painful post-traumatic trigeminal neuropathy'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H539036576">
         <span class="h1">
          PROGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The course of TN is variable. Episodes may last weeks or months, followed by pain-free intervals of weeks to years, although most remissions last for only a few months [
         <a href="#rid30">
          30,37
         </a>
         ]. Recurrence is common, and some patients have concomitant persistent background facial pain. Most often, the condition tends to wax and wane in severity and frequency of pain exacerbations. However, there are no pure natural history studies of TN, most likely because the severity of the pain leads to intervention [
         <a href="#rid70">
          70
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2728410745">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/115871.html" rel="external">
          "Society guideline links: Neuropathic pain"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H10751501">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or email these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topic (see
         <a class="medical medical_basics" href="/z/d/html/16844.html" rel="external">
          "Patient education: Trigeminal neuralgia (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H25">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Symptoms
         </strong>
         – Trigeminal neuralgia (TN) is defined clinically by sudden, usually unilateral, severe, brief, stabbing or lancinating, recurrent episodes of pain in the distribution of one or more branches of the fifth cranial (trigeminal) nerve that are triggered by stimulation of the affected trigeminal division. (See
         <a class="local">
          'Clinical features'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnosis and evaluation
         </strong>
         – The diagnosis of TN is based upon the characteristic clinical features consisting primarily of brief paroxysms of severe pain in the distribution of the trigeminal nerve. (See
         <a class="local">
          'Clinical diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         For all patients with suspected TN, we recommend neuroimaging to help define the underlying cause  (
         <a class="graphic graphic_algorithm graphicRef101663" href="/z/d/graphic/101663.html" rel="external">
          algorithm 1
         </a>
         ). Magnetic resonance imaging (MRI) is the preferred imaging method because of its higher resolution compared with computed tomography (CT). (See
         <a class="local">
          'Determining the etiology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Differential diagnosis
         </strong>
         – Uncommon causes of headache and craniofacial pain in the differential of TN include short-lasting unilateral neuralgiform headache attacks, cluster-tic syndrome, first bite syndrome, and primary stabbing headache. In addition, TN can sometimes be confused with dental causes of pain. Although less likely to be confused with TN, the differential diagnosis also includes various causes of painful trigeminal neuropathy, such as acute herpes zoster, postherpetic neuralgia, and trauma to the trigeminal nerve. (See
         <a class="local">
          'Differential diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Medical treatment
         </strong>
         – Pharmacologic therapy is used for initial treatment of most patients with TN. (See
         <a class="local">
          'Medical treatment'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For patients with TN who require pain control, we recommend
         <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">
          carbamazepine
         </a>
         or
         <a class="drug drug_general" data-topicid="9467" href="/z/d/drug information/9467.html" rel="external">
          oxcarbazepine
         </a>
         as initial preventive therapy (
         <a class="grade" href="https:///uptodate/show/grade_1" rel="external">
          Grade 1A
         </a>
         ). These agents have been shown effective in several placebo-controlled clinical trials. (See
         <a class="local">
          'First-line therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For patients with TN who are intolerant of or have contraindications to
         <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">
          carbamazepine
         </a>
         and
         <a class="drug drug_general" data-topicid="9467" href="/z/d/drug information/9467.html" rel="external">
          oxcarbazepine
         </a>
         , we suggest treatment with
         <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">
          gabapentin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9545" href="/z/d/drug information/9545.html" rel="external">
          lamotrigine
         </a>
         , or
         <a class="drug drug_general" data-topicid="9062" href="/z/d/drug information/9062.html" rel="external">
          baclofen
         </a>
         based on limited evidence of efficacy (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). We add an agent from another pharmacologic class for patients with a partial response to monotherapy. Other experts advise early surgical referral for patients who fail to respond to first-line therapy. (See
         <a class="local">
          'Alternatives and adjuncts to first-line therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Rescue therapy can provide short-term analgesia for patients with TN while oral medications are titrated or during breakthrough attacks. Available agents include intranasal or intravenous infusion of
         <a class="drug drug_general" data-topicid="9558" href="/z/d/drug information/9558.html" rel="external">
          lidocaine
         </a>
         , intravenous
         <a class="drug drug_general" data-topicid="9769" href="/z/d/drug information/9769.html" rel="external">
          phenytoin
         </a>
         or
         <a class="drug drug_general" data-topicid="8480" href="/z/d/drug information/8480.html" rel="external">
          fosphenytoin
         </a>
         , or subcutaneous injections of
         <a class="drug drug_general" data-topicid="9968" href="/z/d/drug information/9968.html" rel="external">
          sumatriptan
         </a>
         . (See
         <a class="local">
          'Rescue therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Surgery for medically refractory cases
         </strong>
         – For patients with TN refractory to medical therapy, it is reasonable to discuss options for surgical therapy using microvascular decompression (for TN caused by compression of the trigeminal nerve root), various types of rhizotomy, or gamma knife radiosurgery. The decision to have surgery and the choice among surgical options will be influenced by individual circumstances including patient preference, adverse effect profile of the available techniques, and expertise of the local center. (See
         <a class="local">
          'Surgery for medically refractory TN'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1793318522">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges Zahid H Bajwa, MD, who contributed to earlier versions of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia 2018; 38:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cruccu G, Di Stefano G, Truini A. Trigeminal Neuralgia. N Engl J Med 2020; 383:754.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Love S, Coakham HB. Trigeminal neuralgia: pathology and pathogenesis. Brain 2001; 124:2347.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bowsher D. Trigeminal neuralgia: an anatomically oriented review. Clin Anat 1997; 10:409.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hamlyn PJ. Neurovascular relationships in the posterior cranial fossa, with special reference to trigeminal neuralgia. 2. Neurovascular compression of the trigeminal nerve in cadaveric controls and patients with trigeminal neuralgia: quantification and influence of method. Clin Anat 1997; 10:380.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gronseth G, Cruccu G, Alksne J, et al. Practice parameter: the diagnostic evaluation and treatment of trigeminal neuralgia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology and the European Federation of Neurological Societies. Neurology 2008; 71:1183.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Antonini G, Di Pasquale A, Cruccu G, et al. Magnetic resonance imaging contribution for diagnosing symptomatic neurovascular contact in classical trigeminal neuralgia: a blinded case-control study and meta-analysis. Pain 2014; 155:1464.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cheng TM, Cascino TL, Onofrio BM. Comprehensive study of diagnosis and treatment of trigeminal neuralgia secondary to tumors. Neurology 1993; 43:2298.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Linskey ME, Jho HD, Jannetta PJ. Microvascular decompression for trigeminal neuralgia caused by vertebrobasilar compression. J Neurosurg 1994; 81:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ildan F, Göçer AI, Bağdatoğlu H, et al. Isolated trigeminal neuralgia secondary to distal anterior inferior cerebellar artery aneurysm. Neurosurg Rev 1996; 19:43.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Figueiredo PC, Brock M, De Oliveira AM Júnior, Prill A. Arteriovenous malformation in the cerebellopontine angle presenting as trigeminal neuralgia. Arq Neuropsiquiatr 1989; 47:61.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Matthies C, Samii M. Management of 1000 vestibular schwannomas (acoustic neuromas): clinical presentation. Neurosurgery 1997; 40:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Haddad FS, Taha JM. An unusual cause for trigeminal neuralgia: contralateral meningioma of the posterior fossa. Neurosurgery 1990; 26:1033.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mohanty A, Venkatrama SK, Rao BR, et al. Experience with cerebellopontine angle epidermoids. Neurosurgery 1997; 40:24.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Love S, Hilton DA, Coakham HB. Central demyelination of the Vth nerve root in trigeminal neuralgia associated with vascular compression. Brain Pathol 1998; 8:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hilton DA, Love S, Gradidge T, Coakham HB. Pathological findings associated with trigeminal neuralgia caused by vascular compression. Neurosurgery 1994; 35:299.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gass A, Kitchen N, MacManus DG, et al. Trigeminal neuralgia in patients with multiple sclerosis: lesion localization with magnetic resonance imaging. Neurology 1997; 49:1142.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Truini A, Prosperini L, Calistri V, et al. A dual concurrent mechanism explains trigeminal neuralgia in patients with multiple sclerosis. Neurology 2016; 86:2094.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dilwali S, Mark I, Waubant E. MRI lesions can often precede trigeminal neuralgia symptoms by years in multiple sclerosis. J Neurol Neurosurg Psychiatry 2023; 94:189.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Meaney JF, Watt JW, Eldridge PR, et al. Association between trigeminal neuralgia and multiple sclerosis: role of magnetic resonance imaging. J Neurol Neurosurg Psychiatry 1995; 59:253.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ghislain B, Rabinstein AA, Braksick SA. Etiologies and Utility of Diagnostic Tests in Trigeminal Neuropathy. Mayo Clin Proc 2022; 97:1318.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fromm GH, Terrence CF, Maroon JC. Trigeminal neuralgia. Current concepts regarding etiology and pathogenesis. Arch Neurol 1984; 41:1204.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Obermann M, Yoon MS, Ese D, et al. Impaired trigeminal nociceptive processing in patients with trigeminal neuralgia. Neurology 2007; 69:835.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maarbjerg S, Gozalov A, Olesen J, Bendtsen L. Trigeminal neuralgia--a prospective systematic study of clinical characteristics in 158 patients. Headache 2014; 54:1574.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           MacDonald BK, Cockerell OC, Sander JW, Shorvon SD. The incidence and lifetime prevalence of neurological disorders in a prospective community-based study in the UK. Brain 2000; 123 ( Pt 4):665.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Hecke O, Austin SK, Khan RA, et al. Neuropathic pain in the general population: a systematic review of epidemiological studies. Pain 2014; 155:654.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cruccu G. Trigeminal Neuralgia. Continuum (Minneap Minn) 2017; 23:396.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Katusic S, Williams DB, Beard CM, et al. Epidemiology and clinical features of idiopathic trigeminal neuralgia and glossopharyngeal neuralgia: similarities and differences, Rochester, Minnesota, 1945-1984. Neuroepidemiology 1991; 10:276.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Childs AM, Meaney JF, Ferrie CD, Holland PC. Neurovascular compression of the trigeminal and glossopharyngeal nerve: three case reports. Arch Dis Child 2000; 82:311.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Katusic S, Beard CM, Bergstralh E, Kurland LT. Incidence and clinical features of trigeminal neuralgia, Rochester, Minnesota, 1945-1984. Ann Neurol 1990; 27:89.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fleetwood IG, Innes AM, Hansen SR, Steinberg GK. Familial trigeminal neuralgia. Case report and review of the literature. J Neurosurg 2001; 95:513.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Panchagnula S, Sularz AK, Kahle KT. Familial Trigeminal Neuralgia Cases Implicate Genetic Factors in Disease Pathogenesis. JAMA Neurol 2019; 76:9.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pan SL, Yen MF, Chiu YH, et al. Increased risk of trigeminal neuralgia after hypertension: a population-based study. Neurology 2011; 77:1605.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Siqueira SR, Teixeira MJ, Siqueira JT. Clinical characteristics of patients with trigeminal neuralgia referred to neurosurgery. Eur J Dent 2009; 3:207.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Teruel A, Ram S, Kumar SK, et al. Prevalence of hypertension in patients with trigeminal neuralgia. J Headache Pain 2009; 10:199.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lin KH, Chen YT, Fuh JL, Wang SJ. Increased risk of trigeminal neuralgia in patients with migraine: A nationwide population-based study. Cephalalgia 2015.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maarbjerg S, Gozalov A, Olesen J, Bendtsen L. Concomitant persistent pain in classical trigeminal neuralgia--evidence for different subtypes. Headache 2014; 54:1173.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zakrzewska JM, Linskey ME. Trigeminal neuralgia. BMJ 2014; 348:g474.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cruccu G, Finnerup NB, Jensen TS, et al. Trigeminal neuralgia: New classification and diagnostic grading for practice and research. Neurology 2016; 87:220.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Siqueira SR, Nóbrega JC, Valle LB, et al. Idiopathic trigeminal neuralgia: clinical aspects and dental procedures. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2004; 98:311.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nurmikko TJ. Altered cutaneous sensation in trigeminal neuralgia. Arch Neurol 1991; 48:523.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Di Stefano G, Maarbjerg S, Nurmikko T, et al. Triggering trigeminal neuralgia. Cephalalgia 2018; 38:1049.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sjaastad O, Pareja JA, Zukerman E, et al. Trigeminal neuralgia. Clinical manifestations of first division involvement. Headache 1997; 37:346.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pareja JA, Barón M, Gili P, et al. Objective assessment of autonomic signs during triggered first division trigeminal neuralgia. Cephalalgia 2002; 22:251.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fromm GH, Graff-Radford SB, Terrence CF, Sweet WH. Pre-trigeminal neuralgia. Neurology 1990; 40:1493.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Evans RW, Graff-Radford SB, Bassiur JP. Pretrigeminal neuralgia. Headache 2005; 45:242.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wright E, Evans J. Oral pre-trigeminal neuralgia pain: clinical differential diagnosis and descriptive study results. Cranio 2014; 32:193.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           von Eckardstein KL, Keil M, Rohde V. Unnecessary dental procedures as a consequence of trigeminal neuralgia. Neurosurg Rev 2015; 38:355.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bendtsen L, Zakrzewska JM, Abbott J, et al. European Academy of Neurology guideline on trigeminal neuralgia. Eur J Neurol 2019; 26:831.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee A, McCartney S, Burbidge C, et al. Trigeminal neuralgia occurs and recurs in the absence of neurovascular compression. J Neurosurg 2014; 120:1048.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goh BT, Poon CY, Peck RH. The importance of routine magnetic resonance imaging in trigeminal neuralgia diagnosis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2001; 92:424.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Borges A, Casselman J. Imaging the trigeminal nerve. Eur J Radiol 2010; 74:323.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Blitz AM, Northcutt B, Shin J, et al. Contrast-Enhanced CISS Imaging for Evaluation of Neurovascular Compression in Trigeminal Neuralgia: Improved Correlation with Symptoms and Prediction of Surgical Outcomes. AJNR Am J Neuroradiol 2018; 39:1724.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Anderson VC, Berryhill PC, Sandquist MA, et al. High-resolution three-dimensional magnetic resonance angiography and three-dimensional spoiled gradient-recalled imaging in the evaluation of neurovascular compression in patients with trigeminal neuralgia: a double-blind pilot study. Neurosurgery 2006; 58:666.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cai J, Xin ZX, Zhang YQ, et al. Diagnostic value of 3D time-of-flight MRA in trigeminal neuralgia. J Clin Neurosci 2015; 22:1343.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cruccu G, Gronseth G, Alksne J, et al. AAN-EFNS guidelines on trigeminal neuralgia management. Eur J Neurol 2008; 15:1013.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lambru G, Matharu MS. SUNCT, SUNA and trigeminal neuralgia: different disorders or variants of the same disorder? Curr Opin Neurol 2014; 27:325.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Linkov G, Morris LG, Shah JP, Kraus DH. First bite syndrome: incidence, risk factors, treatment, and outcomes. Laryngoscope 2012; 122:1773.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wiffen PJ, Derry S, Moore RA, Kalso EA. Carbamazepine for chronic neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev 2014; :CD005451.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Campbell FG, Graham JG, Zilkha KJ. Clinical trial of carbazepine (tegretol) in trigeminal neuralgia. J Neurol Neurosurg Psychiatry 1966; 29:265.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rockliff BW, Davis EH. Controlled sequential trials of carbamazepine in trigeminal neuralgia. Arch Neurol 1966; 15:129.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Killian JM, Fromm GH. Carbamazepine in the treatment of neuralgia. Use of side effects. Arch Neurol 1968; 19:129.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nicol CF. A four year double-blind study of tegretol in facial pain. Headache 1969; 9:54.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Di Stefano G, La Cesa S, Truini A, Cruccu G. Natural history and outcome of 200 outpatients with classical trigeminal neuralgia treated with carbamazepine or oxcarbazepine in a tertiary centre for neuropathic pain. J Headache Pain 2014; 15:34.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Attal N, Cruccu G, Baron R, et al. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol 2010; 17:1113.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nurmikko TJ, Eldridge PR. Trigeminal neuralgia--pathophysiology, diagnosis and current treatment. Br J Anaesth 2001; 87:117.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yuan M, Zhou HY, Xiao ZL, et al. Efficacy and Safety of Gabapentin vs. Carbamazepine in the Treatment of Trigeminal Neuralgia: A Meta-Analysis. Pain Pract 2016; 16:1083.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zakrzewska JM, Chaudhry Z, Nurmikko TJ, et al. Lamotrigine (lamictal) in refractory trigeminal neuralgia: results from a double-blind placebo controlled crossover trial. Pain 1997; 73:223.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lunardi G, Leandri M, Albano C, et al. Clinical effectiveness of lamotrigine and plasma levels in essential and symptomatic trigeminal neuralgia. Neurology 1997; 48:1714.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bennetto L, Patel NK, Fuller G. Trigeminal neuralgia and its management. BMJ 2007; 334:201.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fromm GH, Terrence CF, Chattha AS. Baclofen in the treatment of trigeminal neuralgia: double-blind study and long-term follow-up. Ann Neurol 1984; 15:240.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Morra ME, Elgebaly A, Elmaraezy A, et al. Therapeutic efficacy and safety of Botulinum Toxin A Therapy in Trigeminal Neuralgia: a systematic review and meta-analysis of randomized controlled trials. J Headache Pain 2016; 17:63.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lechin F, van der Dijs B, Lechin ME, et al. Pimozide therapy for trigeminal neuralgia. Arch Neurol 1989; 46:960.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhang J, Yang M, Zhou M, et al. Non-antiepileptic drugs for trigeminal neuralgia. Cochrane Database Syst Rev 2013; :CD004029.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Niki Y, Kanai A, Hoshi K, Okamoto H. Immediate analgesic effect of 8% lidocaine applied to the oral mucosa in patients with trigeminal neuralgia. Pain Med 2014; 15:826.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fromm GH, Aumentado D, Terrence CF. A clinical and experimental investigation of the effects of tizanidine in trigeminal neuralgia. Pain 1993; 53:265.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lindström P, Lindblom U. The analgesic effect of tocainide in trigeminal neuralgia. Pain 1987; 28:45.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moore D, Chong MS, Shetty A, Zakrzewska JM. A systematic review of rescue analgesic strategies in acute exacerbations of primary trigeminal neuralgia. Br J Anaesth 2019; 123:e385.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhou X, Shen Y, Zhao C, Luo F. Lidocaine aerosol sprayed on oral and/or nasal mucosa for the rescue of acute trigeminal neuralgia exacerbations: A retrospective study. Cephalalgia 2023; 43:3331024231168086.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kanai A, Suzuki A, Kobayashi M, Hoka S. Intranasal lidocaine 8% spray for second-division trigeminal neuralgia. Br J Anaesth 2006; 97:559.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stavropoulou E, Argyra E, Zis P, et al. The Effect of Intravenous Lidocaine on Trigeminal Neuralgia: A Randomized Double Blind Placebo Controlled Trial. ISRN Pain 2014; 2014:853826.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cheshire WP. Fosphenytoin: an intravenous option for the management of acute trigeminal neuralgia crisis. J Pain Symptom Manage 2001; 21:506.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tate R, Rubin LM, Krajewski KC. Treatment of refractory trigeminal neuralgia with intravenous phenytoin. Am J Health Syst Pharm 2011; 68:2059.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vargas A, Thomas K. Intravenous fosphenytoin for acute exacerbation of trigeminal neuralgia: case report and literature review. Ther Adv Neurol Disord 2015; 8:187.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Andersen ASS, Heinskou TB, Asghar MS, et al. Intravenous fosphenytoin as treatment for acute exacerbation of trigeminal neuralgia: A prospective systematic study of 15 patients. Cephalalgia 2022; 42:1138.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Muñoz-Vendrell A, Teixidor S, Sala-Padró J, et al. Intravenous lacosamide and phenytoin for the treatment of acute exacerbations of trigeminal neuralgia: A retrospective analysis of 144 cases. Cephalalgia 2022; 42:1031.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McCleane GJ. Intravenous infusion of phenytoin relieves neuropathic pain: a randomized, double-blinded, placebo-controlled, crossover study. Anesth Analg 1999; 89:985.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kanai A, Saito M, Hoka S. Subcutaneous sumatriptan for refractory trigeminal neuralgia. Headache 2006; 46:577.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kanai A, Suzuki A, Osawa S, Hoka S. Sumatriptan alleviates pain in patients with trigeminal neuralgia. Clin J Pain 2006; 22:677.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kao CH, Lee MH, Yang JT, et al. Percutaneous Radiofrequency Rhizotomy Is Equally Effective for Trigeminal Neuralgia Patients with or Without Neurovascular Compression. Pain Med 2022; 23:807.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gorgulho A, Agazaryan N, Selch M, et al. Immediate Pain Relief Elicited After Radiosurgery for Classical and Symptomatic Trigeminal Neuralgia. Cureus 2019; 11:e4777.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Broggi G, Ferroli P, Franzini A, et al. Role of microvascular decompression in trigeminal neuralgia and multiple sclerosis. Lancet 1999; 354:1878.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sandell T, Eide PK. The effect of microvascular decompression in patients with multiple sclerosis and trigeminal neuralgia. Neurosurgery 2010; 67:749.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ariai MS, Mallory GW, Pollock BE. Outcomes after microvascular decompression for patients with trigeminal neuralgia and suspected multiple sclerosis. World Neurosurg 2014; 81:599.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Przybylowski CJ, Cole TS, Baranoski JF, et al. Radiosurgery for multiple sclerosis-related trigeminal neuralgia: retrospective review of long-term outcomes. J Neurosurg 2018; :1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Martin S, Teo M, Suttner N. The effectiveness of percutaneous balloon compression in the treatment of trigeminal neuralgia in patients with multiple sclerosis. J Neurosurg 2015; 123:1507.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Worm J, Noory N, Smilkov EA, et al. Efficacy of surgical treatment in patients with trigeminal neuralgia secondary to multiple sclerosis: A prospective study of 18 cases with evaluation of outcome and complications by independent evaluators. Cephalalgia 2023; 43:3331024231167130.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zakrzewska JM, Akram H. Neurosurgical interventions for the treatment of classical trigeminal neuralgia. Cochrane Database Syst Rev 2011; :CD007312.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jannetta PJ. Microsurgical management of trigeminal neuralgia. Arch Neurol 1985; 42:800.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barker FG 2nd, Jannetta PJ, Bissonette DJ, et al. The long-term outcome of microvascular decompression for trigeminal neuralgia. N Engl J Med 1996; 334:1077.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zakrzewska JM, Lopez BC, Kim SE, Coakham HB. Patient reports of satisfaction after microvascular decompression and partial sensory rhizotomy for trigeminal neuralgia. Neurosurgery 2005; 56:1304.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Broggi G, Ferroli P, Franzini A, et al. Microvascular decompression for trigeminal neuralgia: comments on a series of 250 cases, including 10 patients with multiple sclerosis. J Neurol Neurosurg Psychiatry 2000; 68:59.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Piatt JH Jr, Wilkins RH. Microvascular decompression for tic douloureux. Neurosurgery 1984; 15:456.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barker FG 2nd, Jannetta PJ, Bissonette DJ, Jho HD. Trigeminal numbness and tic relief after microvascular decompression for typical trigeminal neuralgia. Neurosurgery 1997; 40:39.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lopez BC, Hamlyn PJ, Zakrzewska JM. Systematic review of ablative neurosurgical techniques for the treatment of trigeminal neuralgia. Neurosurgery 2004; 54:973.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Huang B, Yao M, Chen Q, et al. Efficacy and Safety of Awake Computed Tomography-Guided Percutaneous Balloon Compression of Trigeminal Ganglion for Trigeminal Neuralgia. Pain Med 2021; 22:2700.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mansano AM, Frederico TN, Valentin REB, et al. Percutaneous Radiofrequency Ablation for Trigeminal Neuralgia Management: A Randomized, Double-Blinded, Sham-Controlled Clinical Trial. Pain Med 2023; 24:234.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mittal B, Thomas DG. Controlled thermocoagulation in trigeminal neuralgia. J Neurol Neurosurg Psychiatry 1986; 49:932.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zakrzewska JM, Jassim S, Bulman JS. A prospective, longitudinal study on patients with trigeminal neuralgia who underwent radiofrequency thermocoagulation of the Gasserian ganglion. Pain 1999; 79:51.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           North RB, Kidd DH, Piantadosi S, Carson BS. Percutaneous retrogasserian glycerol rhizotomy. Predictors of success and failure in treatment of trigeminal neuralgia. J Neurosurg 1990; 72:851.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Siqueira SR, da Nóbrega JC, de Siqueira JT, Teixeira MJ. Frequency of postoperative complications after balloon compression for idiopathic trigeminal neuralgia: prospective study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2006; 102:e39.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Young RF, Vermeulen SS, Grimm P, et al. Gamma Knife radiosurgery for treatment of trigeminal neuralgia: idiopathic and tumor related. Neurology 1997; 48:608.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sheehan J, Pan HC, Stroila M, Steiner L. Gamma knife surgery for trigeminal neuralgia: outcomes and prognostic factors. J Neurosurg 2005; 102:434.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Flickinger JC, Pollock BE, Kondziolka D, et al. Does increased nerve length within the treatment volume improve trigeminal neuralgia radiosurgery? A prospective double-blind, randomized study. Int J Radiat Oncol Biol Phys 2001; 51:449.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maesawa S, Salame C, Flickinger JC, et al. Clinical outcomes after stereotactic radiosurgery for idiopathic trigeminal neuralgia. J Neurosurg 2001; 94:14.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Petit JH, Herman JM, Nagda S, et al. Radiosurgical treatment of trigeminal neuralgia: evaluating quality of life and treatment outcomes. Int J Radiat Oncol Biol Phys 2003; 56:1147.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Régis J, Metellus P, Hayashi M, et al. Prospective controlled trial of gamma knife surgery for essential trigeminal neuralgia. J Neurosurg 2006; 104:913.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lopez BC, Hamlyn PJ, Zakrzewska JM. Stereotactic radiosurgery for primary trigeminal neuralgia: state of the evidence and recommendations for future reports. J Neurol Neurosurg Psychiatry 2004; 75:1019.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smith ZA, Gorgulho AA, Bezrukiy N, et al. Dedicated linear accelerator radiosurgery for trigeminal neuralgia: a single-center experience in 179 patients with varied dose prescriptions and treatment plans. Int J Radiat Oncol Biol Phys 2011; 81:225.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chen JC, Girvigian M, Greathouse H, et al. Treatment of trigeminal neuralgia with linear accelerator radiosurgery: initial results. J Neurosurg 2004; 101 Suppl 3:346.
          </a>
         </li>
         <li class="breakAll">
          Heros RC, Heros DA, Schumacher JM, Marsden CD. Principles of neurosurgery. In: Neurology in Clinical Practice, Bradley WG, Daroff RB, Fenichel GM (Eds), Butterworth Heinemann, Philadelphia 2004. p.963.
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 5283 Version 53.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29368949" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32813951" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Trigeminal Neuralgia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11701590" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Trigeminal neuralgia: pathology and pathogenesis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9358972" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Trigeminal neuralgia: an anatomically oriented review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9358968" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Neurovascular relationships in the posterior cranial fossa, with special reference to trigeminal neuralgia. 2. Neurovascular compression of the trigeminal nerve in cadaveric controls and patients with trigeminal neuralgia: quantification and influence of method.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18716236" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Practice parameter: the diagnostic evaluation and treatment of trigeminal neuralgia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology and the European Federation of Neurological Societies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24785270" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Magnetic resonance imaging contribution for diagnosing symptomatic neurovascular contact in classical trigeminal neuralgia: a blinded case-control study and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8232946" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Comprehensive study of diagnosis and treatment of trigeminal neuralgia secondary to tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8207508" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Microvascular decompression for trigeminal neuralgia caused by vertebrobasilar compression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8738365" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Isolated trigeminal neuralgia secondary to distal anterior inferior cerebellar artery aneurysm.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2669692" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Arteriovenous malformation in the cerebellopontine angle presenting as trigeminal neuralgia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8971818" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Management of 1000 vestibular schwannomas (acoustic neuromas): clinical presentation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2194138" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : An unusual cause for trigeminal neuralgia: contralateral meningioma of the posterior fossa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8971820" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Experience with cerebellopontine angle epidermoids.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9458161" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Central demyelination of the Vth nerve root in trigeminal neuralgia associated with vascular compression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7969838" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Pathological findings associated with trigeminal neuralgia caused by vascular compression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9339705" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Trigeminal neuralgia in patients with multiple sclerosis: lesion localization with magnetic resonance imaging.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27164695" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : A dual concurrent mechanism explains trigeminal neuralgia in patients with multiple sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36396446" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : MRI lesions can often precede trigeminal neuralgia symptoms by years in multiple sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7673952" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Association between trigeminal neuralgia and multiple sclerosis: role of magnetic resonance imaging.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35787858" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Etiologies and Utility of Diagnostic Tests in Trigeminal Neuropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6487105" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Trigeminal neuralgia. Current concepts regarding etiology and pathogenesis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17724285" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Impaired trigeminal nociceptive processing in patients with trigeminal neuralgia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25231219" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Trigeminal neuralgia--a prospective systematic study of clinical characteristics in 158 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10733998" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : The incidence and lifetime prevalence of neurological disorders in a prospective community-based study in the UK.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24291734" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Neuropathic pain in the general population: a systematic review of epidemiological studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28375911" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Trigeminal Neuralgia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1798430" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Epidemiology and clinical features of idiopathic trigeminal neuralgia and glossopharyngeal neuralgia: similarities and differences, Rochester, Minnesota, 1945-1984.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10735840" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Neurovascular compression of the trigeminal and glossopharyngeal nerve: three case reports.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2301931" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Incidence and clinical features of trigeminal neuralgia, Rochester, Minnesota, 1945-1984.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11565877" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Familial trigeminal neuralgia. Case report and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30398541" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Familial Trigeminal Neuralgia Cases Implicate Genetic Factors in Disease Pathogenesis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21998318" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Increased risk of trigeminal neuralgia after hypertension: a population-based study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19756195" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Clinical characteristics of patients with trigeminal neuralgia referred to neurosurgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19277836" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Prevalence of hypertension in patients with trigeminal neuralgia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26692399" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Increased risk of trigeminal neuralgia in patients with migraine: A nationwide population-based study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24842632" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Concomitant persistent pain in classical trigeminal neuralgia--evidence for different subtypes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24534115" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Trigeminal neuralgia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27306631" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Trigeminal neuralgia: New classification and diagnostic grading for practice and research.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15356468" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Idiopathic trigeminal neuralgia: clinical aspects and dental procedures.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2021366" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Altered cutaneous sensation in trigeminal neuralgia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28708009" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Triggering trigeminal neuralgia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9237408" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Trigeminal neuralgia. Clinical manifestations of first division involvement.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12100085" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Objective assessment of autonomic signs during triggered first division trigeminal neuralgia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2215936" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Pre-trigeminal neuralgia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15836600" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Pretrigeminal neuralgia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25000161" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Oral pre-trigeminal neuralgia pain: clinical differential diagnosis and descriptive study results.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25418511" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Unnecessary dental procedures as a consequence of trigeminal neuralgia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30860637" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : European Academy of Neurology guideline on trigeminal neuralgia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24506241" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Trigeminal neuralgia occurs and recurs in the absence of neurovascular compression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11598578" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : The importance of routine magnetic resonance imaging in trigeminal neuralgia diagnosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20227216" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Imaging the trigeminal nerve.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30139749" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Contrast-Enhanced CISS Imaging for Evaluation of Neurovascular Compression in Trigeminal Neuralgia: Improved Correlation with Symptoms and Prediction of Surgical Outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16575330" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : High-resolution three-dimensional magnetic resonance angiography and three-dimensional spoiled gradient-recalled imaging in the evaluation of neurovascular compression in patients with trigeminal neuralgia: a double-blind pilot study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26077938" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Diagnostic value of 3D time-of-flight MRA in trigeminal neuralgia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18721143" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : AAN-EFNS guidelines on trigeminal neuralgia management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24792341" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : SUNCT, SUNA and trigeminal neuralgia: different disorders or variants of the same disorder?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22573579" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : First bite syndrome: incidence, risk factors, treatment, and outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24719027" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Carbamazepine for chronic neuropathic pain and fibromyalgia in adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5327969" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Clinical trial of carbazepine (tegretol) in trigeminal neuralgia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5329617" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Controlled sequential trials of carbamazepine in trigeminal neuralgia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4877400" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Carbamazepine in the treatment of neuralgia. Use of side effects.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4896266" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : A four year double-blind study of tegretol in facial pain.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24912658" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Natural history and outcome of 200 outpatients with classical trigeminal neuralgia treated with carbamazepine or oxcarbazepine in a tertiary centre for neuropathic pain.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20402746" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11460800" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Trigeminal neuralgia--pathophysiology, diagnosis and current treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26891784" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Efficacy and Safety of Gabapentin vs. Carbamazepine in the Treatment of Trigeminal Neuralgia: A Meta-Analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9415509" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Lamotrigine (lamictal) in refractory trigeminal neuralgia: results from a double-blind placebo controlled crossover trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9191794" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Clinical effectiveness of lamotrigine and plasma levels in essential and symptomatic trigeminal neuralgia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17255614" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Trigeminal neuralgia and its management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6372646" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Baclofen in the treatment of trigeminal neuralgia: double-blind study and long-term follow-up.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27377706" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Therapeutic efficacy and safety of Botulinum Toxin A Therapy in Trigeminal Neuralgia: a systematic review and meta-analysis of randomized controlled trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2673161" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Pimozide therapy for trigeminal neuralgia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24297506" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Non-antiepileptic drugs for trigeminal neuralgia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24506194" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Immediate analgesic effect of 8% lidocaine applied to the oral mucosa in patients with trigeminal neuralgia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8351156" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : A clinical and experimental investigation of the effects of tizanidine in trigeminal neuralgia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3103044" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : The analgesic effect of tocainide in trigeminal neuralgia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31208761" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : A systematic review of rescue analgesic strategies in acute exacerbations of primary trigeminal neuralgia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37032614" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Lidocaine aerosol sprayed on oral and/or nasal mucosa for the rescue of acute trigeminal neuralgia exacerbations: A retrospective study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16882684" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Intranasal lidocaine 8% spray for second-division trigeminal neuralgia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27335883" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : The Effect of Intravenous Lidocaine on Trigeminal Neuralgia: A Randomized Double Blind Placebo Controlled Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11397609" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Fosphenytoin: an intravenous option for the management of acute trigeminal neuralgia crisis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22011984" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Treatment of refractory trigeminal neuralgia with intravenous phenytoin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26136846" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Intravenous fosphenytoin for acute exacerbation of trigeminal neuralgia: case report and literature review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35469443" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Intravenous fosphenytoin as treatment for acute exacerbation of trigeminal neuralgia: A prospective systematic study of 15 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35469475" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Intravenous lacosamide and phenytoin for the treatment of acute exacerbations of trigeminal neuralgia: A retrospective analysis of 144 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10512276" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Intravenous infusion of phenytoin relieves neuropathic pain: a randomized, double-blinded, placebo-controlled, crossover study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16643550" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Subcutaneous sumatriptan for refractory trigeminal neuralgia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16988562" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Sumatriptan alleviates pain in patients with trigeminal neuralgia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34264315" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Percutaneous Radiofrequency Rhizotomy Is Equally Effective for Trigeminal Neuralgia Patients with or Without Neurovascular Compression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31367495" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Immediate Pain Relief Elicited After Radiosurgery for Classical and Symptomatic Trigeminal Neuralgia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10584731" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Role of microvascular decompression in trigeminal neuralgia and multiple sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20651626" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : The effect of microvascular decompression in patients with multiple sclerosis and trigeminal neuralgia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24056218" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Outcomes after microvascular decompression for patients with trigeminal neuralgia and suspected multiple sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30544359" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Radiosurgery for multiple sclerosis-related trigeminal neuralgia: retrospective review of long-term outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26067615" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : The effectiveness of percutaneous balloon compression in the treatment of trigeminal neuralgia in patients with multiple sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37072908" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Efficacy of surgical treatment in patients with trigeminal neuralgia secondary to multiple sclerosis: A prospective study of 18 cases with evaluation of outcome and complications by independent evaluators.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21901707" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : Neurosurgical interventions for the treatment of classical trigeminal neuralgia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4026617" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : Microsurgical management of trigeminal neuralgia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8598865" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : The long-term outcome of microvascular decompression for trigeminal neuralgia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15918947" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : Patient reports of satisfaction after microvascular decompression and partial sensory rhizotomy for trigeminal neuralgia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10601403" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : Microvascular decompression for trigeminal neuralgia: comments on a series of 250 cases, including 10 patients with multiple sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6483160" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : Microvascular decompression for tic douloureux.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8971822" id="rid103" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          104 : Trigeminal numbness and tic relief after microvascular decompression for typical trigeminal neuralgia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15046666" id="rid104" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          105 : Systematic review of ablative neurosurgical techniques for the treatment of trigeminal neuralgia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34320638" id="rid105" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          106 : Efficacy and Safety of Awake Computed Tomography-Guided Percutaneous Balloon Compression of Trigeminal Ganglion for Trigeminal Neuralgia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36029256" id="rid106" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          107 : Percutaneous Radiofrequency Ablation for Trigeminal Neuralgia Management: A Randomized, Double-Blinded, Sham-Controlled Clinical Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3746327" id="rid107" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          108 : Controlled thermocoagulation in trigeminal neuralgia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9928776" id="rid108" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          109 : A prospective, longitudinal study on patients with trigeminal neuralgia who underwent radiofrequency thermocoagulation of the Gasserian ganglion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2338568" id="rid109" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          110 : Percutaneous retrogasserian glycerol rhizotomy. Predictors of success and failure in treatment of trigeminal neuralgia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17052623" id="rid110" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          111 : Frequency of postoperative complications after balloon compression for idiopathic trigeminal neuralgia: prospective study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9065534" id="rid111" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          112 : Gamma Knife radiosurgery for treatment of trigeminal neuralgia: idiopathic and tumor related.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15796376" id="rid112" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          113 : Gamma knife surgery for trigeminal neuralgia: outcomes and prognostic factors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11567820" id="rid113" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          114 : Does increased nerve length within the treatment volume improve trigeminal neuralgia radiosurgery? A prospective double-blind, randomized study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11147887" id="rid114" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          115 : Clinical outcomes after stereotactic radiosurgery for idiopathic trigeminal neuralgia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12829153" id="rid115" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          116 : Radiosurgical treatment of trigeminal neuralgia: evaluating quality of life and treatment outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16776335" id="rid116" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          117 : Prospective controlled trial of gamma knife surgery for essential trigeminal neuralgia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15201363" id="rid117" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          118 : Stereotactic radiosurgery for primary trigeminal neuralgia: state of the evidence and recommendations for future reports.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21236592" id="rid118" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          119 : Dedicated linear accelerator radiosurgery for trigeminal neuralgia: a single-center experience in 179 patients with varied dose prescriptions and treatment plans.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15537188" id="rid119" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          120 : Treatment of trigeminal neuralgia with linear accelerator radiosurgery: initial results.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
